United States. Food and Drug Administration
FDA Lifts Clinical Hold on Rein Therapeutics' LTI-03 Trial
Rein Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has lifted the full clinical hold on the Company's Phase 2 "RENEW" trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). This decision follows a review of Rein's submission, which